Skip to content

A cohort study of individualized High-Frequency Chest Wall Oscillation based on airway resonance frequency (Fres) guided recovery of sputum volume/characteristics and airway mechanical characteristics in hospitalized AECOPD patients

A Randomized Controlled Study of Individualized High-Frequency Chest Wall Oscillation Guided by Airway Resonance Frequency (Fres) for Airway Clearance in Hospitalized AECOPD Patients and a Cohort study for the Recovery of Sputum Volume/Characteristics and Airway Mechanical Properties

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125071
Enrollment
Unknown
Registered
2026-05-21
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Experimental group:On the basis of receiving all the above standard conventional treatments, add "personalized high-frequency chest wall oscillation (HFCWO) therapy based on your individual airway res
Control group:On the basis of receiving all of the above standard conventional treatments, add 'using conventional fixed-parameter HFCWO therapy'.

Sponsors

China Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Clear diagnosis: Meeting the GOLD diagnostic criteria for chronic obstructive pulmonary disease (COPD), and hospitalized due to acute exacerbation. 2. Age 40–85 years old, male or female. 3.Capable of spontaneous expectoration; daily sputum volume = 10 mL or sputum is viscous and difficult to discharge. 4. Able to complete pulmonary function or IOS testing within 48 hours after admission, with valid Fres values obtained. 5. No contraindications to HFCWO, able to cooperate with treatment and sputum collection. 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Existing pneumothorax, mediastinal emphysema, or severe hemodynamic instability. 2. Clear bronchiectasis and combined with macroptysis (> 200 mL/24h). 3. Combined with severe heart failure (NYHA class IV) or unstable arrhythmia. 4. Patients with severe thorax deformity affecting HFCWO treatment after lung resection. 5. Severe consciousness or cognitive impairment, unable to cooperate with the intervention. 6. Participating in other interventional clinical trials. 7. Participants are judged by the investigator or attending physician to be unsuitable.

Design outcomes

Primary

MeasureTime frame
Sputum wet weight;

Secondary

MeasureTime frame
Sputum characteristics and rheological indices;Gas exchange indices;Changes in pulmonary function;Clinical symptoms improvement;Treatment tolerance;Adverse Events;Length of hospital stay;Recovery status of acute exacerbation;

Countries

China

Contacts

Public ContactWang Siyuan

China Japan Friendship Hospital

wsyzmx@sina.com+86 186 1848 0531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026